The Europe companion diagnostics market is estimated to develop with a CAGR of 13.06% during the forecasting period of 2022 to 2030, reaching a revenue share of $3997.91 million by 2030.

EUROPE COMPANION DIAGNOSTICS MARKET FORECAST 2022-2030

Europe Companion Diagnostics Market by Technology (in Situ Hybridization, Polymerase Chain Reaction, Immunohistochemistry, Next Generation Sequencing, Other Technologies) Market by Indication (Oncology, Neurology, Infectious Diseases, Other Indications) Market by End-user (Pharmaceutical and Biopharmaceutical Companies, Reference Laboratories, Other End-users) Market by Products & Services (Assay Kits and Reagents, Software & Services) by Geography

Request free sample

The Europe companion diagnostics market is estimated to develop with a CAGR of 13.06% during the forecasting period of 2022 to 2030, reaching a revenue share of $3997.91 million by 2030.

Some of the key factors ascribed to the market growth of the region include the increasing focus on collaborative research and development for the progression of precision medicine technologies, as well as the rising demand for technologically advanced medical diagnostics. However, the Europe companion diagnostics market growth is likely to be restrained due to country-specific technology evaluation and reimbursement policies as well as the lack of support from private payers in terms of promoting companion diagnostic testing.

Europe Companion Diagnostics Market

To know more about this report, request a free sample copy

The Europe companion diagnostics market growth study covers a detailed analysis of the United Kingdom, France, Germany, Spain, Poland, the Netherlands, Italy, and Rest of Europe. Unlike other European nations, the companion diagnostics evaluation process in the United Kingdom is incorporated with technology appraisal for an associated targeted drug, thus avoiding delays in the decision-making process. The country’s government has also set up an assessment program for companion diagnostic tests when various tests from identical biomarkers are available. However, since the exact funding mechanism for companion diagnostics is unclear among various stakeholders in the United Kingdom, companies are paying a substantial amount for these tests on a temporary basis.

Conversely, the market growth in Germany is mainly credited to the rising need for targeted diagnoses in order to minimize unwanted expenditure on high-cost targeted treatments, without the foreknowledge of its success and advantages. Prominent companies, such as Dr. Regenold GmbH, Protagen AG, Evotec AG, R Biopharm AG, Qiagen NV, and Seimens Healthineers, have also revised their market penetration strategies in the country to generate value for all stakeholders, including physicians, policymakers, patients, and others.

Furthermore, a new law was enforced in the country in 2015 regarding establishing a time limit for evaluating innovative diagnostic tests, including companion diagnostics. This factor also represented a notable development in the right direction towards addressing the restraints prevalent in the Germany companion diagnostics market. Hence, these drivers are expected to influence the market growth in Europe during the forecast years.

The Europe companion diagnostics market is segmented into technology, indication, products & services, and end-user. The indication category includes oncology, neurology, infectious diseases, and other indications. The rise in cancers globally is set to bolster the deployment of companion diagnostics. These devices are utilized in the oncology segment for developing highly accurate medicine and therapy for specific cancer cases.

The neurology segment constitutes companion diagnostics tests used to precisely diagnose patients diagnosed with neurological conditions like Aicardi syndrome, neurodegeneration, Asperger syndrome, neuralgia, and various others. Moreover, companion diagnostics in neurology also offer support for accurate drug development as well as drug discovery by performing clinical trials.

Top players operating in the Europe companion diagnostics market include Biocartis, Almac Group, Biomerieux, etc.

Biocartis, headquartered in Belgium, is a cutting-edge commercial stage molecular diagnostics (MDx) company that designs next-generation diagnostic solutions to benefit doctors, patients, as well as the healthcare industry.

The company also provides advanced analyses, diagnostic tools, and a diagnostic technology platform for the multiplexed detection of bio-analyses used in a varied range of applications. Furthermore, Biocartis has expanded its research and development initiatives in the infectious disease division and the field of oncology, as well.

Report Synopsis

Report ScopeDetails
Market Forecast Years2022-2030
Base Year2021
Market Historical Years2018-2021
Forecast UnitsRevenue ($ Million)
Segment AnalyzedTechnology, Indication, Products & Services, End-User
Countries AnalyzedThe United Kingdom, France, Germany, Spain, Poland, the Netherlands, Italy, and Rest of Europe
Companies Analyzed

Abbott Laboratories, Almac Group, Arup Laboratories, Biocartis, Biomerieux SA, Danaher Corporation, GE Healthcare, Genomic Health, Illumina Inc, Qiagen NV, Agilent, Roche Diagnostics, Sysmex Corporation, Thermo Fisher Scientific Inc

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • KEY DRIVERS
        • GROWING NUMBER OF CANCER CASES AND MORTALITIES
        • INCREASING POPULARITY OF PRECISION MEDICINES
        • RISING NUMBER OF ADVERSE DRUG REACTION CASES
      • KEY RESTRAINTS
        • COUNTRY-SPECIFIC REIMBURSEMENT ISSUES
        • FREQUENT CASES OF LEAKAGE IN COMPANION DIAGNOSTICS FOR ONCOLOGY
    1. KEY ANALYTICS
      • IMPACT OF COVID-19 ON COMPANION DIAGNOSTICS MARKET
      • KEY MARKET TRENDS
      • PORTER’S FIVE FORCES ANALYSIS
        • BUYERS POWER
        • SUPPLIERS POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • VALUE CHAIN ANALYSIS
      • KEY BUYING CRITERIA
      • REGULATORY FRAMEWORK
    2. MARKET BY TECHNOLOGY
      • IN SITU HYBRIDIZATION
      • POLYMERASE CHAIN REACTION
      • IMMUNOHISTOCHEMISTRY
      • NEXT GENERATION SEQUENCING
      • OTHER TECHNOLOGIES
    3. MARKET BY INDICATION
      • ONCOLOGY
      • NEUROLOGY
      • INFECTIOUS DISEASES
      • OTHER INDICATIONS
    4. MARKET BY END-USER
      • PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
      • REFERENCE LABORATORIES
      • OTHER END-USERS
    5. MARKET BY PRODUCTS & SERVICES
      • ASSAY KITS AND REAGENTS
      • SOFTWARE & SERVICES
    6. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • UNITED KINGDOM
          • GERMANY
          • FRANCE
          • SPAIN
          • ITALY
          • POLAND
          • NETHERLANDS
          • REST OF EUROPE
    1. COMPETITIVE LANDSCAPE
      • KEY STRATEGIC DEVELOPMENTS
        • MERGERS & ACQUISITIONS
        • PRODUCT LAUNCHES & DEVELOPMENTS
        • PARTNERSHIPS & AGREEMENTS
      • COMPANY PROFILES
        • ABBOTT LABORATORIES
        • AGILENT
        • ALAMC GROUP
        • ARUP LABORATORIES
        • BIOCARTIS
        • BIOMERIEUX SA
        • DANAHER CORPORATION
        • GE HEALTHCARE
        • GENOMIC HEALTH
        • ILLUMINA INC
        • MYRIAD GENETICS INC
        • QIAGEN NV
        • ROCHE DIAGNOSTICS
        • SYSMEX CORPORATION
        • THERMO FISHER SCIENTIFIC INC

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – COMPANION DIAGNOSTICS

    TABLE 2: NEW CASES OF CANCER PATIENTS IN 2020

    TABLE 3: EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 4: EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 5: EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 6: EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 7: EUROPE COMPANION DIAGNOSTICS MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 8: EUROPE COMPANION DIAGNOSTICS MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 9: EUROPE COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 10: EUROPE COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 11: EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 12: EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 13: LEADING PLAYERS OPERATING IN EUROPE COMPANION DIAGNOSTICS MARKET

    TABLE 14: LIST OF MERGERS & ACQUISITIONS

    TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

    TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS          

    LIST OF FIGURES

    FIGURE 1: CDX LEAKAGE

    FIGURE 2: KEY MARKET TRENDS

    FIGURE 3: PORTER’S FIVE FORCES ANALYSIS

    FIGURE 4: OPPORTUNITY MATRIX

    FIGURE 5: VENDOR LANDSCAPE

    FIGURE 6: VALUE CHAIN ANALYSIS

    FIGURE 7: FDA GUIDELINES FOR CDX APPROVAL

    FIGURE 8: EUROPE COMPANION DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021

    FIGURE 9: EUROPE COMPANION DIAGNOSTICS MARKET, BY IN SITU HYBRIDIZATION, 2022-2030 (IN $ MILLION)

    FIGURE 10: EUROPE COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2030 (IN $ MILLION)

    FIGURE 11: EUROPE COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2030 (IN $ MILLION)

    FIGURE 12: EUROPE COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2030 (IN $ MILLION)

    FIGURE 13: EUROPE COMPANION DIAGNOSTICS MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)

    FIGURE 14: EUROPE COMPANION DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY INDICATION, IN 2021

    FIGURE 15: EUROPE COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2030 (IN $ MILLION)

    FIGURE 16: EUROPE COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2030 (IN $ MILLION)

    FIGURE 17: EUROPE COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2030 (IN $ MILLION)

    FIGURE 18: EUROPE COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATIONS, 2022-2030 (IN $ MILLION)

    FIGURE 19: EUROPE COMPANION DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

    FIGURE 20: EUROPE COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)

    FIGURE 21: EUROPE COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2030 (IN $ MILLION)

    FIGURE 22: EUROPE COMPANION DIAGNOSTICS MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)

    FIGURE 23: EUROPE COMPANION DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY PRODUCTS & SERVICES, IN 2021

    FIGURE 24: EUROPE COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2030 (IN $ MILLION)

    FIGURE 25: EUROPE COMPANION DIAGNOSTICS MARKET, BY SOFTWARE & SERVICES, 2022-2030 (IN $ MILLION)

    FIGURE 26: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

    FIGURE 27: UNITED KINGDOM COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 28: GERMANY COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 29: FRANCE COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 30: SPAIN COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 31: ITALY COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 32: POLAND COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 33: NETHERLANDS COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 34: REST OF EUROPE COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)       

    1. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • UNITED KINGDOM
          • GERMANY
          • FRANCE
          • SPAIN
          • ITALY
          • POLAND
          • NETHERLANDS
          • REST OF EUROPE
    1. MARKET BY TECHNOLOGY
      • IN SITU HYBRIDIZATION
      • POLYMERASE CHAIN REACTION
      • IMMUNOHISTOCHEMISTRY
      • NEXT GENERATION SEQUENCING
      • OTHER TECHNOLOGIES
    2. MARKET BY INDICATION
      • ONCOLOGY
      • NEUROLOGY
      • INFECTIOUS DISEASES
      • OTHER INDICATIONS
    3. MARKET BY END-USER
      • PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
      • REFERENCE LABORATORIES
      • OTHER END-USERS
    4. MARKET BY PRODUCTS & SERVICES
      • ASSAY KITS AND REAGENTS
      • SOFTWARE & SERVICES

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type